Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as sterile eye drops for ocular administration. It reduces intra‑ocular pressure by enhancing aqueous humor outflow and is indicated for the treatment of open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Monoprost complies with European Union pharmaceutical regulations and is distributed across multiple international markets.

Monoprost (latanoprost) is a prostaglandin analog used in ocular hypotensive therapy to lower intra‑ocular pressure.

Open-angle glaucoma: reduces intra‑ocular pressure to slow visual field loss. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Pseudoexfoliative glaucoma: helps control pressure in this secondary open‑angle condition.

Common Side Effects: - Eye redness (hyperemia) - Increased eyelash length and thickness - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision - Mild ocular discomfort

Serious or Rare Side Effects: - Uveitis or severe ocular inflammation - Macular edema leading to vision changes - Allergic reaction with swelling or rash - Paradoxical increase in intra‑ocular pressure - Endophthalmitis or severe eye infection

Before initiating therapy, evaluate baseline intra‑ocular pressure and ocular health. - Assess for active eye infection: postpone use until resolved. - Monitor iris color and eyelash changes: document any progression. - Caution in patients with a history of uveitis or corneal transplantation. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost may interact with other ocular agents.

Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: risk of additive ocular effects. - Combination with ocular corticosteroids: may diminish prostaglandin efficacy.

Moderate Interactions (Monitor Closely):\n- Co‑administration with beta‑blocker eye drops: monitor intra‑ocular pressure for excessive reduction. - Use with alpha‑agonist eye drops: observe pressure changes. - Systemic antihistamines: may increase ocular dryness, advise patient monitoring.